Lactoferrin

When a newborn receives its first drops of colostrum, its immune system gains emergency protection — colostrum contains 10–15 times more lactoferrin than mature breast milk. This fact illustrates how critical lactoferrin is for mucosal defence when a person's own immunity has yet to develop. The same principle — reproducing native protection — underlies its use in dental formulations.

What It Is

Lactoferrin is a multifunctional glycoprotein of the transferrin family, with a molecular weight of ~80 kDa. It is secreted by neutrophils, mucosal epithelial cells, and exocrine glands. In the oral cavity it is found in saliva (80–1,000 µg/mL, concentration rises during inflammation) and is particularly concentrated in gingival crevicular fluid.

Structurally, lactoferrin consists of two symmetrical N- and C-lobes, each containing one high-affinity Fe³⁺-binding site (association constant Ka = 10²² M⁻¹ — among the highest of any iron-transport protein).

Bovine lactoferrin (bLF), derived from milk whey, is the commercially used form — widely available, ~69% amino acid homology with human lactoferrin, fully replicating antibacterial activity.

How It Works

Iron deprivation mechanism (bacteriostasis). Most pathogenic oral bacteria require Fe³⁺ ions for DNA synthesis, the electron transport chain, and virulence factor production. Lactoferrin competes with bacterial siderophores for iron, creating a local "iron deficiency" that arrests pathogen growth without directly killing them. This is bacteriostasis, not a bactericidal mechanism — which is important for preserving commensal flora.

Lactoferricin — direct bactericide. At acidic pH and in the presence of peptidases, lactoferrin undergoes proteolytic cleavage at its N-terminal region to generate lactoferricin B (bLfcin) — a 25-amino-acid cationic peptide. Lactoferricin has direct bactericidal activity: it inserts into bacterial membranes and forms pores. Minimum inhibitory concentrations (MIC) for S. mutans: 0.1–0.5 µg/mL.

Permeabilisation of gram-negative bacteria. Lactoferrin binds to LPS (lipopolysaccharide) on the outer membrane of gram-negative pathogens (P. gingivalis, F. nucleatum), destabilising the membrane and rendering these bacteria vulnerable to lysozyme. This is why the lactoferrin + lysozyme combination covers both proteins' weaknesses: lysozyme alone is nearly ineffective against gram-negatives, while lactoferrin "opens the door."

Antifungal action. Lactoferrin and lactoferricin inhibit Candida albicans adhesion to mucosa, disrupt biofilm formation, and suppress the transition from the yeast form to the pathogenic hyphal form. This is especially relevant for patients after antibiotic therapy.

Efficacy

Inhibition of cariogenic biofilm (PMID: 21248359)

Berlutti et al. (2011) showed that lactoferrin inhibits the glucosyltransferases of S. mutans — the key enzymes that anchor the biofilm to enamel. IC₅₀ for GtfB was 1.6 µM (≈0.13 mg/mL). This explains why lactoferrin doesn't merely slow S. mutans growth but disrupts the very architecture of the cariogenic biofilm.

Clinical enzyme complex for xerostomia (PMID: 11999007)

Tenovuo (2002): the triple enzyme system (lysozyme + lactoferrin + lactoperoxidase) in clinical trials in xerostomia patients demonstrated: subjective improvement in 70–80% of patients, reduced caries activity, and decreased candidal mucosal involvement. This confirms that it is the combined action of the three enzymes, rather than each alone, that replicates salivary defence.

Antiviral activity (PMID: 24512891)

Wakabayashi et al. (2014): lactoferrin binds to heparan sulphate proteoglycans on host cell surfaces, competing with viruses for adhesion points. This is relevant for QDRO formulas in cold-and-flu season: lactoferrin in a mouthwash or throat spray reduces the risk of viral upper respiratory tract infections.

Safety

Lactoferrin is a native human protein with no allergenic potential at topical application doses. Bovine lactoferrin (bLF) has a 40-year history of use in infant formula without any documented adverse effects.

• Listed in EU CosIng without concentration restrictions
• GRAS status (FDA, food ingredient)
• Not allergenic at clinical concentrations — milk allergy is not equivalent to lactoferrin allergy, since the primary milk allergens are casein and β-lactoglobulin

Important stability note: lactoferrin loses up to 30% of activity at pH < 3.5 and denatures above 70°C — requiring appropriate manufacturing conditions.

Role in the QDRO Formula

Lactoferrin is the central component of the QDRO enzyme system, operating synergistically with lysozyme and lactoperoxidase. In the context of the v.pro "Second Enamel" paste, lactoferrin serves a dual role:

1. Antibacterial protection (bacteriostasis + lactoferricin + anti-biofilm effect)
2. Anti-inflammatory gum support through reduced bacterial load

Optimal concentration in toothpaste: 0.1–0.2%. In mouthwash (longer contact time): up to 0.3%.

Brand verdict: we use it — the indispensable partner of lysozyme, and a key antibacterial component of the QDRO triple enzyme system.

---

Sources:

• Loimaranta V et al. (2009). Lactoferrin and its derived peptides: an antimicrobial approach to clinical practice. J Craniomaxillofac Surg. PMID: 19595618
• Berlutti F et al. (2011). Lactoferrin inhibits Streptococcus mutans-induced dental caries by inhibiting glucosyltransferase. J Dent Res. PMID: 21248359
• Tenovuo J. (2002). Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia. Oral Dis. PMID: 11999007
• Wakabayashi H et al. (2014). Lactoferrin for prevention of common viral infections. J Infect Chemother. PMID: 24512891
• Edde L et al. (2001). Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol. PMID: 11254502